MIRA INFORM REPORT

 

 

Report Date :

09.10.2013

 

IDENTIFICATION DETAILS

 

Name :

UNITED BIOTECH PRIVATE LIMITED

 

 

Registered Office :

E-142, Saket, New Delhi – 110017

 

 

Country :

India

 

 

Financials (as on) :

31.03.2011

 

 

Date of Incorporation :

31.01.1997

 

 

Com. Reg. No.:

55-084814

 

 

Capital Investment / Paid-up Capital :

Rs.45.363 Millions

 

 

CIN No.:

[Company Identification No.]

U24239DL1997PTC084814

 

 

TAN No.:

[Tax Deduction & Collection Account No.]

DELU02630F

 

 

PAN No.:

[Permanent Account No.]

AAACU1839L

 

 

Legal Form :

Private Limited Liability Company

 

 

Line of Business :

Manufacturer of Pharmaceutical Products such as Formulations, Injections etc.

 

 

No. of Employees :

Not Divulged

 

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba (45)

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

 

Maximum Credit Limit :

USD 7200000

 

 

Status :

Satisfactory

 

 

Payment Behaviour :

Usually Correct

 

 

Litigation :

Clear

 

 

Comments :

Subject is an established company having a satisfactory track record. Management has failed to file the financial data of 2011-2012 with the government department.

 

As per previous year’s, the performance of the company seems to be good. Trade relations are reported to be fair. Business is active. Payments are reported to be usually correct and as per commitment.

 

The company can be considered for normal business dealings at usual trade terms and condition.

 

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

 

 

ECGC Country Risk Classification List – March 31st, 2013

 

Country Name

Previous Rating

(31.12.2012)

Current Rating

(31.03.2013)

India

A1

A1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 

INDIAN ECONOMIC OVERVIEW

 

We are living in a world where volatility and uncertainty have become the New Normal. We saw a change of government in countries like Tunisia, Egypt, Libya and Vietnam. Once powerful countries in Europe are now fighting for bankruptcy. We have taken growth in the developing part of the world for granted but economic growth in China and India has begun to slow. Companies that were synonymous with their product categories just a few years ago are now no longer in existence. Kodak, the inventor of the digital camera had to wind up its operations, HMV, the British entertainment retailing company and Borders, once the second largest bookstore have shut down due to their inability to evolve their business models with the changing time. Readers’ Digest, Thomson Register are no more !

 

There is another megatrend happening. The World order is changing as economic power shifts from West to East. According to McKinsey study, it took Britain more than 100 years to double its economic output per person during its industrial revolution and the US later took more than 50 years to do the same. More than a century later, China and India have doubled their GDP per capital in 12 and 18 years respectively. By 2020, emerging Asia will become the world’s largest consuming block, overtaking North America.

 

The years after the outbreak of the global financial crisis, the world economy continues to remain fragile. The Indian economy demonstrated remarkable resilience in the initial years of the contagion but finally lost ground last year. GDP growth slowed down. Currency has been weakening. There is a marked deceleration in agriculture, industry and services. Dampening sentiment led to a cut-back in investment as well as private consumption expenditure.  Inflation remained at high levels fuelled by the pressure from the food and fuel sectors. The large fiscal and current account deficit s continued to cause grave concern. It is imperative that India regains its growth trajectory of 8-9 % sooner than later. This is crucially important given the need to create gainful livelihood opportunities for the millions living in poverty as also the large contingent of young people joining the job market every year.

 

 

RBI DEFAULTERS’ LIST STATUS

 

Subject’s name is not enlisted as a defaulter in the publicly available RBI Defaulters’ list.

 

 

EPF (Employee Provident Fund) DEFAULTERS’ LIST STATUS

 

Subject’s name is not enlisted as a defaulter in the publicly available EPF (Employee Provident Fund) Defaulters’ list as of 31-03-2012.

 

 

INFORMATION DECLINED

 

MANAGEMENT NON-COOPERATIVE [91-11-40651100]

 

 

LOCATIONS

 

Registered Office :

E-142, Saket, New Delhi – 110017, India

Tel. No.:

91-11-26855082/ 40651100

Fax No.:

91-11-26855082/ 66607096

E-Mail :

ubpl@del3.vsnl.net.in

ubpl@del3.vsnl.net.in

accounts@unitedbiotechindia.com

administration@unitedbiotechindia.com

Website :

http://www.unitedbiotechindia.com

 

 

Corporate Office :

FC/B-1 (Extn.), Mohan Co-operative Industrial Estate, Mathura Road, New Delhi – 110044, India

Tel. No.:

91-11-40651100/ 66607095/ 66403098/ 99/ 26940762

Fax No.:

91-11-66607096/ 66607091

E-Mail:

ubpl@vsnl.com

 

 

Factory :

Bagbania, Baddi, Nalagarh Road, District Solan – 174101, Himachal Pradesh, India

Te. No.:

91-1795-236904/ 5/ 6

Fax No.:

91-1795-236604

E-Mail :

plant@unitedbiotechindia.com

 

 

DIRECTORS

 

AS ON 29.09.2012

 

Name :

Mr. Rajiv  Kumar

Designation :

Whole-time Director

Address :

E-142, Saket, Delhi – 110017, India

Date of Birth/Age :

09.04.1963

Qualification :

Bachelor in Pharma

Date of Appointment :

22.04.2008

DIN No.:

00073944

Other Directorship :

 

S.No.

CIN/LLPIN

Name of the Company/ LLP

Current designation of the Director/ Designated Partner

Date of appointment at current designation

Original date of appointment

Company/ LLP Status

Defaulting status

1

U24239DL1997PTC084814

UNITED BIOTECH PRIVATE LIMITED

Whole-time director

22/04/2008

31/01/1997

Active

NO

2

U24233DL2010PTC199814

SORGEN HEALTHCARE PRIVATE LIMITED

Director

08/03/2010

08/03/2010

Active

NO

3

U24297DL2011PTC227673

UMANO HEALTHCARE PRIVATE LIMITED

Director

21/11/2011

21/11/2011

Active

NO

 

Name :

Mrs. Kavita Gakhar

Designation :

Whole-time Director

Address :

E-142, Saket, Delhi – 110017, India

Date of Birth/Age :

11.10.1970

Qualification :

MA

Date of Appointment :

01.08.2007

DIN No.:

00073976

Other Directorship :

 

S.No.

CIN/LLPIN

Name of the Company/ LLP

Current designation of the Director/ Designated Partner

Date of appointment at current designation

Original date of appointment

Company/ LLP Status

Defaulting status

1

U24239DL1997PTC084814

UNITED BIOTECH PRIVATE LIMITED

Whole-time director

01/08/2007

01/08/2002

Active

NO

2

U24233DL2010PTC199814

SORGEN HEALTHCARE PRIVATE LIMITED

Director

08/03/2010

08/03/2010

Active

NO

3

U24297DL2011PTC227673

UMANO HEALTHCARE PRIVATE LIMITED

Director

21/11/2011

21/11/2011

Active

NO

 

Name :

Mrs. Kailash Devi

Designation :

Whole-time Director

Address :

E-142, Saket, Delhi – 110017, India

Qualification :

MA

Date of Appointment :

22.04.2008

DIN No.:

00074289

Other Directorship :

 

S.No.

CIN/LLPIN

Name of the Company/ LLP

Current designation of the Director/ Designated Partner

Date of appointment at current designation

Original date of appointment

Company/ LLP Status

Defaulting status

1

U27101DL1981PTC012739

SUBHAM UDYOG PRIVATE LIMITED

Director

06/06/2001

06/06/2001

Active

NO

2

U24239DL1997PTC084814

UNITED BIOTECH PRIVATE LIMITED

Whole-time director

22/04/2008

01/05/2002

Active

NO

3

U24231DL2011PTC227688

FELIZ LIFECARE PRIVATE LIMITED

Director

21/11/2011

21/11/2011

Active

NO

 

Name :

Mr. Sanjeev Kumar

Designation :

Whole-time Director

Address :

House No. E-142, Saket Malviya Nagar, Delhi – 110017, India

Date of Birth/Age :

26.09.1966

Qualification :

B. Pharma

Date of Appointment :

02.04.2007

DIN No.:

01691559

Other Directorship :

 

S.No.

CIN/LLPIN

Name of the Company/ LLP

Current designation of the Director/ Designated Partner

Date of appointment at current designation

Original date of appointment

Company/ LLP Status

Defaulting status

1

U24239DL1997PTC084814

UNITED BIOTECH PRIVATE LIMITED

Whole-time director

02/04/2007

02/04/2007

Active

NO

2

U27101DL1981PTC012739

SUBHAM UDYOG PRIVATE LIMITED

Director

27/03/2008

27/03/2008

Active

NO

3

U24231DL2011PTC227688

FELIZ LIFECARE PRIVATE LIMITED

Director

21/11/2011

21/11/2011

Active

NO

 

 

MAJOR SHAREHOLDERS / SHAREHOLDING PATTERN

 

AS ON 29.09.2012

 

Names of Shareholders

 

No. of Shares

Rajiv Kumar

59233

Kailash Devi

59233

Kavita Gakhar

59234

Monika Gakhar

59233

Ashwani Kumar

59233

Sanjeev Kumar

98233

Preeti Gakhar

59234

 

 

Total

 

453633

 

 

AS ON 29.09.2012

 

Equity Share Break up (Percentage of Total Equity)

 

Category

 

Percentage

Directors or relatives of Directors

100.00

 

 

Total

 

100.00

 

 

BUSINESS DETAILS

 

Line of Business :

Manufacturer of Pharmaceutical Products such as Formulations, Injections etc.

 

 

GENERAL INFORMATION

 

No. of Employees :

Not Divulged

 

 

Bankers :

·         Oriental Bank of Commerce, Hauz Khas Branch, New Delhi, India

·         Standard Chartered Bank

·         ICICI Bank Limited

·         HDFC Bank Limited

 

 

 

 

Auditors :

 

Name :

VPGS and Company

Chartered Accountants

Address :

3208, II Floor, Mahindra Park, New Delhi-110034, India

Tel. No.:

AAGFA7822G

 

 

CAPITAL STRUCTURE

 

AS ON 29.09.2012

 

Authorised Capital :

No. of Shares

Type

Value

Amount

 

 

 

 

500000

Equity Shares

Rs. 100/- each

Rs. 50.000 Millions

 

 

 

 

 

Issued, Subscribed & Paid-up Capital :

No. of Shares

Type

Value

Amount

 

 

 

 

453633

Equity Shares

Rs. 100/- each

Rs. 45.363 Millions

 

 

 

 

 


 

 

FINANCIAL DATA

[all figures are in Rupees Millions]

 

ABRIDGED BALANCE SHEET

 

SOURCES OF FUNDS

 

31.03.2011

31.03.2010

31.03.2009

SHAREHOLDERS FUNDS

 

 

 

1] Share Capital

45.363

45.363

45.363

2] Share Application Money

0.000

0.000

0.000

3] Reserves & Surplus

1743.614

1236.919

809.765

4] (Accumulated Losses)

0.000

0.000

0.000

NETWORTH

1788.977

1282.282

855.128

LOAN FUNDS

 

 

 

1] Secured Loans

0.000

0.000

1.529

2] Unsecured Loans

0.000

0.000

4.200

TOTAL BORROWING

0.000

0.000

5.729

DEFERRED TAX LIABILITIES

1.268

1.425

1.837

 

 

 

 

TOTAL

1790.245

1283.707

862.694

 

 

 

 

APPLICATION OF FUNDS

 

 

 

 

 

 

 

FIXED ASSETS [Net Block]

444.144

441.043

459.201

Capital work-in-progress

0.000

0.000

0.000

 

 

 

 

INVESTMENT

0.000

0.000

0.000

DEFERREX TAX ASSETS

0.000

0.000

0.000

 

 

 

 

CURRENT ASSETS, LOANS & ADVANCES

 

 

 

 

Inventories

218.535

187.193

174.717

 

Sundry Debtors

185.510

200.319

163.893

 

Cash & Bank Balances

812.299

430.636

97.138

 

Other Current Assets

117.976

83.617

81.368

 

Loans & Advances

221.188

130.262

35.601

Total Current Assets

1555.508

1032.027

552.717

Less : CURRENT LIABILITIES & PROVISIONS

 

 

 

 

Sundry Creditors

0.000

0.000

50.764

 

Other Current Liabilities

105.648

116.045

57.204

 

Provisions

103.759

73.539

41.698

Total Current Liabilities

209.407

189.584

149.666

Net Current Assets

1346.101

842.443

403.051

 

 

 

 

MISCELLANEOUS EXPENSES

0.000

0.221

0.442

 

 

 

 

TOTAL

1790.245

1283.707

862.694

 

 


PROFIT & LOSS ACCOUNT

 

 

PARTICULARS

 

31.03.2011

31.03.2010

31.03.2009

 

SALES

 

 

 

 

 

TOTAL                                    

1266.664

1003.349

810.229

 

 

 

 

 

Less

EXPENSES

 

 

 

 

 

TOTAL                                    

721.952

544.194

476.902

 

 

 

 

 

Less

PROFIT BEFORE INTEREST, TAX, DEPRECIATION AND AMORTISATION

544.712

459.155

(Including Depreciation)

 

 

 

 

 

Less/ Add

DEPRECIATION/ AMORTISATION                    

24.260

26.566

 

 

 

 

 

 

 

PROFIT BEFORE TAX                          

520.452

432.589

333.327

 

 

 

 

 

Less

TAX                                                                 

103.602

73.127

42.050

 

 

 

 

 

 

PROFIT AFTER TAX                            

416.850

359.462

291.277

 

 

 

 

 

Add

TAX Paid U/S 115JB (MAT) Carried Forward

89.845

67.692

0.000

 

 

 

 

 

 

PREVIOUS YEARS’ BALANCE BROUGHT FORWARD

1236.919

809.765

484.360

 

 

 

 

 

 

BALANCE CARRIED TO THE B/S

1743.614

1236.919

809.765

 

 

 

 

 

 

Earnings Per Share (Rs.)

918.91

792.41

642.10

 

 

KEY RATIOS

 

PARTICULARS

 

 

31.03.2011

31.03.2010

31.03.2009

PAT / Total Income

(%)

32.91

35.83

35.95

 

 

 

 

 

Return on Total Assets

(PBT/Total Assets}

(%)

26.03

29.37

32.94

 

 

 

 

 

Return on Investment (ROI)

(PBT/Networth)

 

0.29

0.34

0.39

 

 

 

 

 

Debt Equity Ratio

(Total Debt/Networth)

 

0.00

0.00

0.01

 

 

 

 

 

Current Ratio

(Current Asset/Current Liability)

 

7.43

5.44

3.69

 

 

LOCAL AGENCY FURTHER INFORMATION

 

 

Sr. No.

Check List by Info Agents

Available in Report

(Yes / No)

1]

Year of Establishment

Yes

2]

Locality of the firm

Yes

3]

Constitutions of the firm

Yes

4]

Premises details

No

5]

Type of Business

Yes

6]

Line of Business

Yes

7]

Promoter's background

Yes

8]

No. of employees

No

9]

Name of person contacted

No

10]

Designation of contact person

No

11]

Turnover of firm for last three years

Yes

12]

Profitability for last three years

Yes

13]

Reasons for variation <> 20%

---------------------

14]

Estimation for coming financial year

No

15]

Capital in the business

Yes

16]

Details of sister concerns

No

17]

Major suppliers

No

18]

Major customers

No

19]

Payments terms

No

20]

Export / Import details (if applicable)

No

21]

Market information

---------------------

22]

Litigations that the firm / promoter involved in

----------------------

23]

Banking Details

Yes

24]

Banking facility details

No

25]

Conduct of the banking account

----------------------

26]

Buyer visit details

----------------------

27]

Financials, if provided

Yes

28]

Incorporation details, if applicable

Yes

29]

Last accounts filed at ROC

No

30]

Major Shareholders, if available

Yes

31]

Date of Birth of Proprietor/Partner/Director, if available

Yes

32]

PAN of Proprietor/Partner/Director, if available

No

33]

Voter ID No of Proprietor/Partner/Director, if available

No

34]

External Agency Rating, if available

No

 

 

BUSINESS OPERATIONS

 

This year had been marked as a year of outstanding commercial productions of Baddi unit/ factory of the Company and the Company has performed well in export market as well.

 

The members may note that the new Lyophilizer (Machinery used for manufacturing Lyophilized Injections) acquired by the Company during the previous year has already been installed and production has bee commenced

 

The Company is undertaking major expansion of plant and machinery in the existing unit at Bagbania, Baddi-Nalagarh and expecting the completion of these expansions within this financial year.

 

The export turnover of the Company has been tremendously increased by 10 times to Rs. 35.550 Millions against the previous years export turnover amounting to Rs. 3.546 Millions. The major export markets are Sri Lanka, Philippines, Dominican Republic, Cuba, Nepal, Costarica etc

 

Sri Lanka has proved to be potential market for our export strategy. The Company is having major contracts with the Government of Sri Lanka

 

The Company has already registered its products in Philippines market and continuously distributing these products in that country

 

The Company started its own direct marketing operations in Nepal and efforts are underway for the rapid growth of sale of their products in that country.

 

The Company has already submitted the Dossiers for registering products at Mexico and the registration is on final stages. The Directors are keenly making efforts to get the registration of various products of the Company in Russia as well as major African Countries.

 

 

NEW PRODUCTS LAUNCHED

 

Ertapenem Injection, Cyclosporin Softgelatin Capsules, Cefepime Injection, Cefepime + Tazobactam Injection, Ceftazidime + Tazobactam Injection, Ceftriaxone + Tazobactam Injection, Tigecycline Injection, etc.

 

 

NEW PRODUCTS IN PIPELINE

 

Phenylephrine Injection, Protamine Sulphate Injection, Methotrexate Tablets, Nicardipine Injection (for Export), Nitroglycerine Tablets (for Export) etc.

           

 

BANKERS CHARGES REPORT AS PER REGISTRY

 

Corporate identity number of the company

U24239DL1997PTC084814

Name of the company

UNITED BIOTECH PRIVATE LIMITED

Address of the registered office or of the principal place of  business in India of the company

E-142, Saket, New Delhi – 110017, India

Email : administration@unitedbiotechindia.com

This form is for

Modification of Charge

Charge identification (ID) number of the charge to be modified

90337196

Type of charge

Immovable Property

Book Debts

Floating Charge

Others (Stocks)

Particular of charge holder

Oriental Bank of Commerce, Hauz Khas Institutional Area, New Delhi-110016, India

Email : bm0562@obc.co.in

Nature of instrument creating charge

Supplemental Agreement to secure credit/ loan facilities

Date of instrument Creating the charge

04.02.2013

Amount secured by the charge

Rs. 62.500 Millions

Brief of the principal terms an conditions and extent and operation of the charge

Rate of Interest:

Base Rate +3.50%

 

Terms of Repayment:

Payable on demand.

 

Margin:

As per agreement

 

Extend and Operation of the charge:

100%

 

Others:

The above is to secure the credit facilities of Rs 62.500 Millions, granted by the Bank to the company.

Short particulars of the property or asset(s) charged (including complete address and location of the property)

1.     Hypothecation of Stock and Book Debts both present and future of the company.

2.     Equitable Mortgage of factory land and building situated at Villlage Theliwal (Dhana) Baghbnia Baddi Nalagarh Road, Teh Nalagarh District Solan area 4.48 acre in the name of the company.

Date of Last Modification

13.05.2012

Particulars of the present modification

The various credit facilities enhanced to Rs 62.500 Millions Other term and condition  remain the same

 

 

FIXED ASSETS:

 

·         Land

·         Factory Building

·         Plant and Machinery

·         Electrical Installation

·         Furniture and Fixture

·         Vehicles

·         Computers

·         Office Equipment

·         Capital Work in Progress


 

CMT REPORT (Corruption, Money Laundering & Terrorism]

 

The Public Notice information has been collected from various sources including but not limited to: The Courts, India Prisons Service, Interpol, etc.

 

1]         INFORMATION ON DESIGNATED PARTY

No exist designating subject or any of its beneficial owners, controlling shareholders or senior officers as terrorist or terrorist organization or whom notice had been received that all financial transactions involving their assets have been blocked or convicted, found guilty or against whom a judgement or order had been entered in a proceedings for violating money-laundering, anti-corruption or bribery or international economic or anti-terrorism sanction laws or whose assets were seized, blocked, frozen or ordered forfeited for violation of money laundering or international anti-terrorism laws.

 

2]         Court Declaration :

No records exist to suggest that subject is or was the subject of any formal or informal allegations, prosecutions or other official proceeding for making any prohibited payments or other improper payments to government officials for engaging in prohibited transactions or with designated parties.

 

3]         Asset Declaration :

No records exist to suggest that the property or assets of the subject are derived from criminal conduct or a prohibited transaction.

 

4]         Record on Financial Crime :

            Charges or conviction registered against subject:                                                           None

 

5]         Records on Violation of Anti-Corruption Laws :

            Charges or investigation registered against subject:                                                        None

 

6]         Records on Int’l Anti-Money Laundering Laws/Standards :

            Charges or investigation registered against subject:                                                        None

 

7]         Criminal Records

No available information exist that suggest that subject or any of its principals have been formally charged or convicted by a competent governmental authority for any financial crime or under any formal investigation by a competent government authority for any violation of anti-corruption laws or international anti-money laundering laws or standard.

 

8]         Affiliation with Government :

No record exists to suggest that any director or indirect owners, controlling shareholders, director, officer or employee of the company is a government official or a family member or close business associate of a Government official.

 

9]         Compensation Package :

Our market survey revealed that the amount of compensation sought by the subject is fair and reasonable and comparable to compensation paid to others for similar services.

 

10]        Press Report :

            No press reports / filings exists on the subject.

 


 

CORPORATE GOVERNANCE

 

MIRA INFORM as part of its Due Diligence do provide comments on Corporate Governance to identify management and governance. These factors often have been predictive and in some cases have created vulnerabilities to credit deterioration.

 

Our Governance Assessment focuses principally on the interactions between a company’s management, its Board of Directors, Shareholders and other financial stakeholders.

 

 

CONTRAVENTION

 

Subject is not known to have contravened any existing local laws, regulations or policies that prohibit, restrict or otherwise affect the terms and conditions that could be included in the agreement with the subject.

 

 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs. 61.69

UK Pound

1

Rs. 99.20

Euro

1

Rs. 83.69

 

 

INFORMATION DETAILS

 

Information Gathered by :

PDT

 

 

Report Prepared by :

BVA

 


 

SCORE & RATING EXPLANATIONS

 

SCORE FACTORS

 

RANGE

POINTS

HISTORY

1~10

5

PAID-UP CAPITAL

1~10

5

OPERATING SCALE

1~10

5

FINANCIAL CONDITION

 

 

--BUSINESS SCALE

1~10

5

--PROFITABILIRY

1~10

5

--LIQUIDITY

1~10

5

--LEVERAGE

1~10

5

--RESERVES

1~10

5

--CREDIT LINES

1~10

5

--MARGINS

-5~5

--

DEMERIT POINTS

 

 

--BANK CHARGES

YES/NO

NO

--LITIGATION

YES/NO

NO

--OTHER ADVERSE INFORMATION

YES/NO

NO

MERIT POINTS

 

 

--SOLE DISTRIBUTORSHIP

YES/NO

NO

--EXPORT ACTIVITIES

YES/NO

NO

--AFFILIATION

YES/NO

NO

--LISTED

YES/NO

NO

--OTHER MERIT FACTORS

YES/NO

YES

DEFAULTER

 

 

--RBI

YES/NO

NO

--EPF

YES/NO

NO

TOTAL

 

45

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                  Payment record (10%)

Credit history (10%)                   Market trend (10%)                                Operational size (10%)

 


 

RATING EXPLANATIONS

 

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

--

NB

                                       New Business

 

--

 

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.